In a bittersweet transition, Doug Williams takes on his next big biotech challenge
Doug Williams is moving on.
Just days after sounding taps in bankruptcy court over Codiak BioSciences, where he helped spearhead the work as CEO, Williams is back in the saddle, this time as R&D chief at Sana Biotechnology. And he’s joining the cell and gene therapy pioneer alongside Vertex vet Gary Meininger, who’s taking over as CMO at a crucial time for the biotech.
Williams is a well-known figure in biotech, particularly in the Cambridge/Boston circles. He headed research at Biogen under George Scangos at a critical passage in its history, and counts leading posts at a range of biotechs over the years. His jump today illustrates the value of a lengthy career building relationships throughout the industry. Warm and personable, Williams has always stood out of the crowd in his own generally low-key way.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.